A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough

INTRODUCTION: To determine the optimal dose of sivopixant, a highly selective P2X3 receptor antagonist, for refractory or unexplained chronic cough (RCC/UCC). METHODS: In this phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial, patients received sivopixant 50,...

Descripción completa

Detalles Bibliográficos
Autores principales: McGarvey, Lorcan, Smith, Jaclyn A., Morice, Alyn, Birring, Surinder S., Chung, Kian Fan, Dicpinigaitis, Peter V., Niimi, Akio, Benninger, Michael S., Sher, Mandel, Matsunaga, Yuko, Miyazaki, Sayaka, Machida, Mitsuaki, Ishihara, Hiroyuki, Mahmood, Adnan, Gomez, Juan-Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Cough
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745691/
https://www.ncbi.nlm.nih.gov/pubmed/36512069
http://dx.doi.org/10.1007/s00408-022-00592-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745691/
https://www.ncbi.nlm.nih.gov/pubmed/36512069
http://dx.doi.org/10.1007/s00408-022-00592-5

Ejemplares similares